Adolescent depression: Controlled desipramine treatment and atypical features

✍ Scribed by Rachel G. Klein; Salvatore Mannuzza; Harold S. Koplewicz; Nancy K. Tancer; Manoj Shah; Vera Liang; Mark Davies

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 134 KB
• Volume: 7
• Category: Article
• ISSN: 1091-4269
• DOI: 10.1002/(sici)1520-6394(1998)7:1<15::aid-da3>3.0.co;2-4

✦ Synopsis

The study was designed to test the efficacy of desipramine in adolescents with major depression (MDD). In addition, we assessed the presence of atypical features of MDD, consisting of mood reactivity and two of four associated features (rejection sensitivity, hyperphagia, hypersomnia, and leaden paralysis). Patients were randomized to desipramine (DMI) or placebo for 6 weeks, provided they failed to improve (e.g., meeting MDD criteria and a Hamilton Depression Scale score ³18) after 2 weeks on single blind placebo. Of 94 adolescents (ages 13-18) who were diagnosed as having MDD, 64 entered the study and 62 received placebo for 2 weeks. Of these, 45 were randomized to DMI or placebo. Completer analyses did not reveal significant improvement for the active treatment compared to the placebo. A large proportion of adolescents responded to placebo (50%), suggesting the need for very large samples to detect differential treatment efficacy, should it exist. A relatively high rate of atypical depression was observed (47% in the 64 patients entered). In view of the demonstrated specificity of monoamine oxidase inhibitor efficacy in adults with atypical features of MDD, this clinical subtype may have relevance to future investigation of therapeutic interventions in adolescent MDD.